Telomerase inhibition as an adjuvant anticancer therapy: it is more than just a waiting game.
A telomere maintenance mechanism is essential for cancer cells to divide indefinitely. As telomerase maintains telomeres in the vast majority of human cancers, targeting tumor cells in patients with antitelomerase-based strategies is very appealing. However, as the complexities of telomere dynamics and telomerase regulation and function continue to unfold, translating this knowledge into well-designed clinical trials becomes daunting. Here, the authors discuss potential shortcomings for antitelomerase approaches and predict that inhibition of telomerase will be an effective targeted approach against cancer as a polytherapy in the adjuvant setting.
Elmore
Lynne W
LW
Holt
Shawn E
SE
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D019098:Telomerase / Q000037:antagonists & inhibitors*; D016615:Telomere / Q000378:metabolism
D000970:Antineoplastic Agents; D019098:Telomerase